Literature DB >> 21968148

Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population.

Doron M Behar1, Eynat Kedem, Saharon Rosset, Yonas Haileselassie, Shay Tzur, Zipi Kra-Oz, Walter G Wasser, Yotam Shenhar, Eduardo Shahar, Gamal Hassoun, Carcom Maor, Dawit Wolday, Shimon Pollack, Karl Skorecki.   

Abstract

BACKGROUND: Susceptibility to end-stage kidney disease (ESKD) among HIV-infected Americans of African ancestral heritage has been attributed to APOL1 genetic variation. We determined the frequency of the APOL1 G1 and G2 risk variants together with the prevalence of HIV-associated nephropathy (HIVAN) among individuals of Ethiopian ancestry to determine whether the kidney disease genetic risk is PanAfrican or restricted to West Africa, and can explain the previously reported low risk of HIVAN among Ethiopians.
METHODS: We studied a cohort of 338 HIV-infected individuals of Ethiopian ancestry treated in one Israeli and one Ethiopian center. We sought clinical evidence for HIVAN (serum creatinine >1.4 mg/dl or proteinuria >30 mg/dl in a spot urine sample). Genetic analyses included the genotyping of the APOL1 G1 and G2 variants, and a panel of 33 genomic ancestry-informative markers. Statistical analysis compared clinical and genetic indices for HIV-infected individuals of Ethiopian ancestry and overall Ethiopians to those reported for HIV-infected African-Americans, overall African-Americans, West Africans and non-Africans.
FINDINGS: Three (0.8%) of 338 HIV-infected patients of Ethiopian ancestry showed clinical criteria compatible with renal impairment. Two of these 3 patients also have severe poorly controlled diabetes mellitus. The third nondiabetic patient underwent renal biopsy which ruled out HIVAN. This absence of clinically apparent HIVAN was significantly different from that reported for African-Americans. The APOL1 G1 and G2 risk variants were found, respectively, in 0 and 2 (heterozygote state) of the 338 HIV-infected individuals. Global ancestry and the frequencies of the APOL1 G1 and G2 variants are not statistically different from their frequencies in the general Ethiopian population, but are significantly and dramatically lower than those observed among HIV-infected African-Americans, African-Americans and West Africans.
INTERPRETATION: The coinciding absence of HIVAN and the APOL1 risk variants among HIV-infected individuals of Ethiopian ancestry support a Western rather than Pan-African ancestry risk for ESKD, and can readily explain the lack of HIVAN among individuals of Ethiopian ancestry.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21968148     DOI: 10.1159/000332378

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  39 in total

1.  The new era of APOL1-associated glomerulosclerosis.

Authors:  Barry I Freedman; Carl D Langefeld
Journal:  Nephrol Dial Transplant       Date:  2012-02-02       Impact factor: 5.992

2.  Identifying Darwinian selection acting on different human APOL1 variants among diverse African populations.

Authors:  Wen-Ya Ko; Prianka Rajan; Felicia Gomez; Laura Scheinfeldt; Ping An; Cheryl A Winkler; Alain Froment; Thomas B Nyambo; Sabah A Omar; Charles Wambebe; Alessia Ranciaro; Jibril B Hirbo; Sarah A Tishkoff
Journal:  Am J Hum Genet       Date:  2013-06-13       Impact factor: 11.025

3.  APOL1 variants and kidney disease in people of recent African ancestry.

Authors:  Giulio Genovese; David J Friedman; Martin R Pollak
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

Review 4.  APOL1 and nephropathy progression in populations of African ancestry.

Authors:  Barry I Freedman
Journal:  Semin Nephrol       Date:  2013-09       Impact factor: 5.299

Review 5.  The African diaspora: history, adaptation and health.

Authors:  Charles N Rotimi; Fasil Tekola-Ayele; Jennifer L Baker; Daniel Shriner
Journal:  Curr Opin Genet Dev       Date:  2016-09-16       Impact factor: 5.578

6.  APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans.

Authors:  Alex N Kasembeli; Raquel Duarte; Michèle Ramsay; Pulane Mosiane; Caroline Dickens; Thérèse Dix-Peek; Sophie Limou; Efe Sezgin; George W Nelson; Agnes B Fogo; Stewart Goetsch; Jeffrey B Kopp; Cheryl A Winkler; Saraladevi Naicker
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

Review 7.  HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment.

Authors:  Avi Z Rosenberg; Saraladevi Naicker; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Nat Rev Nephrol       Date:  2015-02-17       Impact factor: 28.314

8.  Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.

Authors:  Atanu K Khatua; Amber M Cheatham; Etty D Kruzel; Pravin C Singhal; Karl Skorecki; Waldemar Popik
Journal:  Am J Physiol Cell Physiol       Date:  2015-04-29       Impact factor: 4.249

Review 9.  Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy.

Authors:  Barry I Freedman; Karl Skorecki
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 8.237

10.  Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt
Journal:  Kidney Int       Date:  2018-02-03       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.